One ALS patient received TRE-515 under the FDA program last year, and early signs suggest the therapy may help stabilize ...

Brooke Eby, a writer, speaker, and social media creator who lives with ALS, has been named ALS Network's Advocate of the Year. Through her advocacy work, Eby has increased awareness and raised more ...

The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...

The new project combines clinical data with advanced analytics and artificial intelligence in an effort to create ...

Every few months for the past three years, Jeff Vierstra has been receiving infusions in his spine that target and disable a ...

ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer, ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

An ALS patient named Kenneth shares how a Neuralink brain implant restored his ability to communicate in his own voice ...

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

Elon Musk highlights Neuralink’s latest breakthrough as ALS patient Kenneth Shock regains ability to communicate. The brain ...